Non-ATP-competitive kinase inhibitors - enhancing selectivity through new inhibition strategies (Q43878954)

27 November 2017

title

Non-ATP-competitive kinase inhibitors - enhancing selectivity through new inhibition strategies (English)

1 reference

27 November 2017

Stephen Harrison

1

1 reference

27 November 2017

Kanad Das

2

1 reference

27 November 2017

Felix Karim

3

1 reference

27 November 2017

Derek Maclean

4

1 reference

27 November 2017

Dirk Mendel

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

Expert Opinion on Drug Discovery

27 November 2017

published in

1 reference

27 November 2017

volume

3

1 reference

27 November 2017

issue

7

1 reference

27 November 2017

page(s)

761-774

1 reference

The protein kinase complement of the human genome

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A template for the protein kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Protein kinases as drug targets in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Recent progress in discovery and development of antimitotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Creating chemical diversity to target protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Protein kinase inhibitors: insights into drug design from structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Discovery and characterization of a substrate selective p38alpha inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

NPC 15437 interacts with the C1 domain of protein kinase C. An analysis using mutant PKC constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide (NPC 15437): A selective inhibitor of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Pseudosubstrate-based peptide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Development of inhibitors for protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Mechanism-based design of a protein kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Designing bisubstrate analog inhibitors for protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Sequence-based design of kinase inhibitors applicable for therapeutics and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Recognition and specificity in protein tyrosine kinase-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Structural basis for the binding of high affinity phosphopeptides to Stat3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Stattic: a small-molecule inhibitor of STAT3 activation and dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Inhibitors of Ras signal transduction as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

High affinity Grb2-SH3 domain ligand incorporating Cbeta-substituted prolines in a Sos-derived decapeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Assembly of Cell Regulatory Systems Through Protein Interaction Domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

21 January 2018

Membrane binding domains

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Localization of protein kinases by anchoring proteins: a theme in signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

PKC-B inhibition: a new therapeutic approach for diabetic complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

PKC isozymes in chronic cardiac disease: possible therapeutic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Therapeutic potential of PKC inhibitors in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Adaptor proteins in protein kinase C-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Peptide modulators of protein-protein interactions in intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Protein kinase C in pain: involvement of multiple isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

PI3-kinase inhibition: a target for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A-kinase anchoring proteins take shape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

AKAP signaling complexes: getting to the heart of the matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Compartmentalized cAMP signalling: a personal perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Characterization of A-kinase-anchoring disruptors using a solution-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Design, Synthesis, and Biological Evaluation of a Potent, PKC Selective, B-Ring Analog of Bryostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

Grb7-based molecular therapeutics in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460441.3.7.761

21 January 2018

Identifiers

DOI

10.1517/17460441.3.7.761

1 reference

27 November 2017

1 reference